The Olivia Newton-John Cancer Research Institute in Melbourne received accreditation in Australia to perform mutation testing using Bio-Rad's droplet digital PCR.
Life Science segment sales grew 10 percent on a currency-neutral basis, benefiting in part from increased sales of Droplet Digital PCR products.
A prospective study used droplet digital PCR to search for treatment-informative EGFR and KRAS mutations in cell-free DNA from non-small cell lung cancer patients.
Bio-Rad reported $570.6 million in revenues in Q4, a 5 percent drop year over year but a 3 percent increase on a currency-neutral basis.
The consortium will analyze data from patients and mouse models in the first year as part of efforts to find ways of detecting tumors earlier.
Spokespersons from Bio-Rad noted that there appears to be an increasing number of researchers using ddPCR for methylation analyses.
The developers of the method are now using the ddPCR approach to create and test assays for early colon cancer detection.
Bio-Rad scientist Jennifer Berman explains how ddPCR can help detect the basic efficiency of CRISPR/Cas9 and other genome editing technologies and more.
The researchers' proof-of-concept paper published in PLOS One demonstrated a method that could lead to more haplotype analysis in genomic studies of diseases.
The agreements are to distribute RainDance's products in Central and Eastern Europe, Italy, Switzerland, Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.
A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.
NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.
In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.
In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.